TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, and antitumor activity of TAS-117 in patients with advanced or metastatic
solid tumors (excluding primary brain tumors) harboring germline PTEN inactivating mutations.